Related Experiment Video
Updated: May 9, 2026

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation
Published on: September 29, 2019
Polymyxin-B endotoxin removal device: making the point on mechanisms of action, clinical effectiveness and possible
Franco Ruberto1, S Ianni, C Babetto
1Department of Anesthesiology and Intensive Care Medicine, Sapienza Universita di Roma, Policlinico Umberto I, viale del Policlinico 155, 00161 Rome, Italy. rube2005@libero.it
Abstract:
In this review, we focus on current information on the apheresis procedures for endotoxins removal with Polymyxin B cartridges (PMX). This device has been designed in 2003 in Japan in order to take advantage of the antibiotic effects of Polymyxins on Gram negative bacteria and endotoxins, by-passing the toxicity shown by the intravenous administration. Although its mechanisms of action are nowadays well-known, we felt the need to sum up all the someway scattered information giving an overall sight on the entire process that brings Polymyxins molecules to function as powerful detergents of the endotoxins from the blood flow. Since the first experiences on humans, over one hundred studies have been published about the clinical use of this device. Even if some of them were limited in number of patients and compliance to international standards, they all converged in showing a highly positive impact of PMX on the improvement of clinic condition and outcome. Recently, more significant and large experiences confirmed the benefits of this treatment on hemodynamic, PaO2/FiO2 ratio, APACHE and SOFA scores and outcome at 28 days even on different typologies of sepsis cases, such as in transplanted patients. Summarizing, this relatively new procedure has proven to be a promising tool against Gram negative and endotoxin sepsis, combining clinical and outcome improvements with a fair cost/effectiveness ratio. Given that, there's still need of wider and more structured clinical studies that could steady the use of this device and widen its fields of applications.
Insights
Polymyxin B (PMX) cartridges offer an effective apheresis method for removing endotoxins, improving patient outcomes in sepsis. Further research is needed to broaden its clinical applications.
Area of Science:
- Medical Technology
- Nephrology
- Critical Care Medicine
Background:
- Endotoxins from Gram-negative bacteria are a major cause of sepsis.
- Intravenous Polymyxin B is toxic, limiting its use.
- Polymyxin B cartridges (PMX) were developed to safely remove endotoxins via apheresis.
Purpose of the Study:
- To review current information on apheresis procedures using Polymyxin B cartridges for endotoxin removal.
- To summarize the mechanisms, clinical use, and effectiveness of PMX in sepsis treatment.
- To highlight the need for further research to expand PMX applications.
Main Methods:
- Review of over one hundred published studies on the clinical use of PMX cartridges.
- Analysis of data on clinical condition, hemodynamic parameters, respiratory function (PaO2/FiO2 ratio), and severity scores (APACHE, SOFA).
- Evaluation of patient outcomes, including 28-day survival, across various sepsis types.
Main Results:
- PMX apheresis demonstrates a positive impact on clinical condition and patient outcomes.
- Studies show improvements in hemodynamic stability, PaO2/FiO2 ratio, and reduced severity scores.
- Benefits are observed in diverse sepsis cases, including those in transplanted patients.
Conclusions:
- Polymyxin B cartridges are a promising tool for treating Gram-negative and endotoxin sepsis.
- PMX offers clinical and outcome improvements with a favorable cost-effectiveness ratio.
- Wider, structured clinical studies are required to solidify PMX use and expand its indications.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Bacterial Toxins
Inhibitors of Gram-positive Cell Wall Synthesis
Antimicrobial Effectiveness
Mechanism of Antibiotic Resistance in MRSA
Gene Regulation in Microbial Communities: Quorum Sensing

